Video
Dr. Jonasch on next steps with belzutifan in renal cell carcinoma
Author(s):
Video Player is loading.
Eric Jonasch, MD, discusses the next research steps with the HIF-2α inhibitor belzutifan in patients with renal cell carcinoma. At the 2022 ASCO Annual Meeting, Jonasch shared findings from the abstract, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.”
In the video, Jonasch says based on the efficacy in LITESPARK-001, the phase 3 LITESPARK-005 study has already been launched. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Related Videos
Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
Laura Bukavina, MD, highlights study of urinary microbiome profiling
Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
ASCO GU recap: Insights on 5 key trials
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
David Braun, MD, on phase 2 trial of an individualized neoantigen therapy for RCC
Related Content
